SYENS:EURONEXT BRUSSELSSyensqo SA/NV Analysis
Data as of 2026-05-25 - not real-time
€66.75
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Syensqo is trading at €66.75, considerably above its DCF fair value of €39.92, suggesting the stock is **overvalued**. The 14‑day RSI of 77.6 places the shares in the *overbought* zone, while a bullish MACD histogram of +0.62 provides only modest upside momentum. Volatility is exceptionally high at 51% over the past 30 days, though the beta of 0.33 indicates limited sensitivity to broader market moves. Fundamentals are weak: revenue fell 6.9% YoY, trailing EPS is –€0.85 and profit margins are near‑zero, yet the company still generates solid operating cash flow and a free cash flow of €468 M. The dividend yield of 2.43% is supported by a very low payout ratio of 7.7%, making the payout *sustainable* despite earnings pressure. Recent corporate actions—an ordinary shareholders’ meeting, a BlackRock participation notice, and the cancellation of previously repurchased shares—signal active governance and potential shifts in capital structure.
Given the disconnect between price and intrinsic value, the overbought technical picture, and the modest growth outlook, the stock presents a **high‑risk, value‑oriented** profile. Investors should weigh the attractive dividend against the negative earnings trend and elevated price volatility before deciding on exposure.
Given the disconnect between price and intrinsic value, the overbought technical picture, and the modest growth outlook, the stock presents a **high‑risk, value‑oriented** profile. Investors should weigh the attractive dividend against the negative earnings trend and elevated price volatility before deciding on exposure.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- RSI in overbought territory
- Price significantly above DCF fair value
- High 30‑day volatility
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Sustainable dividend with low payout ratio
- Stable cash flow despite earnings loss
- Neutral technical trend
Long Term
> 3 yearsCautious
Model confidence: 5/10
Key Factors
- Negative revenue growth and earnings
- Persistent overvaluation relative to fundamentals
- Elevated sector and regulatory risks
Key Metrics & Analysis
Financial Health
Revenue Growth-6.90%
Profit Margin0.05%
ROE-0.80%
ROA2.41%
Debt/Equity41.68
P/B Ratio1.1
Op. Cash Flow€685.0M
Free Cash Flow€467.9M
Technical Analysis
TrendNeutral
RSI77.6
Support€55.42
Resistance€67.03
MA 20€58.48
MA 50€53.23
MA 200€66.43
MACDBullish
VolumeIncreasing
Fear & Greed Index91.61
Valuation
Fair Value€39.92
GradeOvervalued
TypeValue
Dividend Yield2.43%
Risk Assessment
Beta0.33
Volatility51.29%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.